Neuro-Endocrine/Endocrine system: Adrenal cortical carcinoma

Identity

ICD-Topo	C740-C741,C749 ADRENAL GLANDS
ICD-Morpho	8370/3 Adrenal cortical carcinoma
Atlas_Id	5088
Phylum	Neuro-Endocrine/Endocrine system: Adrenal gland::Adrenocortical
WHO/OMS Classification	Neuro-Endocrine/Endocrine system
Other names	Adrenocortical Carcinoma
	Adrenal Tumor
Note	Adrenocortical carcinoma is a rare malignant neoplasm of adrenal glands, which most often presents without any hormonal symptoms. The most common clinical presentation of patients with hormone-secreting adrenocortical carcinoma is that of Cushing's syndrome. Other hormonal hypersecretion syndromes associated with adrenocortical carcinoma include virilization (from androgen-producing tumors), feminization (estrogen-producing tumors), and hyperaldosteronism. Multiple hormones may be produced by a single tumor, causing a mixed clinical picture. In children, virilization is more common because carcinomas have a greater tendency to be presented with a hormonal syndrome.

Clinics and Pathology

Etiology	Adrenal cancer may present as part of rare hereditary syndromes such as Wiedemann-Beckwith syndrome (WBS) linked to 11p15.5 or the Li-Fraumeni syndrome (LFS), associated with germline mutations of the TP53 gene, on 17p. Sometimes carcinomas develop in children with congenital adrenal hyperplasia (CAH) that is caused most frequently by mutations in the CYP21B gene.
Epidemiology	Adrenal cancer is a rare malignancy representing only 0.05% and 0.2% of all cancers worldwide. Women tend to develop functional adrenal cortical carcinomas more commonly than men. Men develop non-functional malignant adrenal tumors more often than women. There is a bimodal distribution in terms of age: young children less than 5 years old, and adults in their 30s and 40s. In Brazil, the incidence of carcinomas is three times more than the international rate
Pathology	Grading and staging: Stage I: disease confined to the adrenal gland without local invasion or distant metastases and the greatest tumor dimension less than 5cm. Stage II: same as stage I but the greatest tumor dimension is greater than 5 cm. Stage III: local invasion that does not involve adjacent organs or regional lymph nodes. Stage IV: distant metastases or invasion into adjacent organs plus regional lymph nodes.
Treatment	Treatment for adrenocortical carcinomas is complete surgical resection; these tumors do not respond well to chemotherapy. Mitotane may be used as a chronic treatment in non-cured cases or prophylactically. Other medications (e.g. ketoconazole, metyrapone, aminoglutethimide) may be given to reduce production of cortisol and other adrenal steroids that is responsible for many of symptoms.
Prognosis	Extremely poor prognosis, with a survival rate at 20% at five years for stage I-II disease.Poor prognostic indicators include: age at diagnosis, tumor size, distant metastases, invasion of vessels, capsule, or adjacent organs, and tumor necrosis. Pediatric patients with a hormonal syndrome are considered to have a better prognosis because the associated signs and symptoms can make the cancer diagnosis easier leading to earlier surgical intervention

Cytogenetics

Cytogenetics Morphological

Only a few karyotyping studies has been performed. Chromosomal analysis revealed a modal number of 61 with consistent structural abnormalities of add(3)(q11), add(9)(p11), and add(16)(ql1) in one case of adult carcinoma and the karyotype 46, XX, t(4;11)(q35;p13) in the another one. Karyotyping of short-term cultured cells from an 11-cm adrenocortical carcinoma in a 3.5-year-old girl revealed the very complex karyotype 46,XX, inv(9)(p11q12)c/[2]/56-57,XX, +2, +4, +5, +7, +8, inv(9)c, +10, +add (13)(p11), +14, +15, +19, +20, +20, +mar[cp19].

Cytogenetics Molecular

Fluorescent in situ hybridization (FISH) studies of carcinomas showed increasing genome instability in carcinoma progression. Loss of heterozygosity (LOH) studies identified allelic losses on chromosomes 11p, 11q, 13q, and 17p. The LOH on 2p16 is strongly associated with the malignant phenotype. Several studies were reported in carcinomas with comparative genomic hybridization (CGH). DNA sequence copy number gains were identified on chromosomes 4, 5, 9q, and 12q and losses on chromosomes 17p, 1p, 2q, 11q, and 9p. All studies showed that the number of genomic changes is closely correlated with tumor behavior. In adenomas, small tumors contain a small or zero number of chromosomal imbalances, and a number of changes increases in larger adenomas and then considerably increases in carcinomas. Of adenomas, the most common alterations were gains of 4q, 17p, 17q and 9q32-qter. Two CGH studies of childhood adrenal tumors showed extensive genetic alterations both in benign and malignant tumors. The copy number changes are distinctly different to those seen in adult tumors thus possibly reflecting different genetic background for these tumors. High-level amplification of 9q34 was very common.

Genes involved and Proteins

Note

A number of genes are implicated in tumor progression from adrenal adenoma to carcinoma; they include both oncogenes and tumor suppressor genes. Progression from adenoma to carcinoma involves a monoclonal proliferation of cells, which, together with other defects, have undergone rearrangements of the chromosomal locus 11p15.5 associated with IGF II hyperexpression and abrogation of expression of the CDKN1C and H19 genes. TP53 is involved in progression to carcinoma in a subset of patients. In childhood ADCC, 50% of children carried germline mutations of TP53. Deletions of the ACTH receptor gene have been recently found in undifferentiated adenomas and in aggressive adrenocortical carcinomas although the frequency of ACTH receptor deletion needs to be more fully examined. Other key oncogenes and tumor suppressor genes remain to be identified although the chromosomal loci that harbor them were identified at 17p, 1p, 2p16, 11q13, and 9p for tumor suppressor genes and chromosomes 4, 5, 9q, and 12 for oncogenes. The 11q13 region harbors the MEN1 gene, however mutations of the gene were not found in adrenal tumors.

Bibliography

Adrenal cortical carcinoma.

Boushey RP, Dackiw AP

Current treatment options in oncology. 2001 ; 2 (4) : 355-364.

PMID 12057116

Androgen-secreting adrenal tumors.

Cordera F, Grant C, van Heerden J, Thompson G, Young W

Surgery. 2003 ; 134 (6) : 874-880.

PMID 14668717

Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications.

Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P

Genes, chromosomes & cancer. 2000 ; 28 (2) : 145-152.

PMID 10824999

Comparative genomic hybridization analysis of adrenocortical tumors of childhood.

Figueiredo BC, Stratakis CA, Sandrini R, DeLacerda L, Pianovsky MA, Giatzakis C, Young HM, Haddad BR

The Journal of clinical endocrinology and metabolism. 1999 ; 84 (3) : 1116-1121.

PMID 10084604

Adrenocortical carcinoma: a single institution experience.

Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ

The American surgeon. 2005 ; 71 (1) : 90-94.

PMID 15757066

Tumor-specific loss of 11p15.5 alleles in del11p13 Wilms tumor and in familial adrenocortical carcinoma.

Henry I, Grandjouan S, Couillin P, Barichard F, Huerre-Jeanpierre C, Glaser T, Philip T, Lenoir G, Chaussain JL, Junien C

Proceedings of the National Academy of Sciences of the United States of America. 1989 ; 86 (9) : 3247-3251.

PMID 2566168

Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization.

James LA, Kelsey AM, Birch JM, Varley JM

British journal of cancer. 1999 ; 81 (2) : 300-304.

PMID 10496356

Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16.

Kjellman M, Roshani L, Teh BT, Kallioniemi OP, Hg A, Gray S, Farnebo LO, Holst M, Bckdahl M, Larsson C

The Journal of clinical endocrinology and metabolism. 1999 ; 84 (2) : 730-735.

PMID 10022445

Complex karyotype in a childhood adrenocortical carcinoma.

Mertens F, Kullendorff CM, Moll C, Alumets J, Mandahl N

Cancer genetics and cytogenetics. 1998 ; 105 (2) : 190-192.

PMID 9723041

Adrenocortical carcinoma: diagnosis, evaluation and treatment.

Ng L, Libertino JM

The Journal of urology. 2003 ; 169 (1) : 5-11.

PMID 12478091

Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage.

Russell AJ, Sibbald J, Haak H, Keith WN, McNicol AM

British journal of cancer. 1999 ; 81 (4) : 684-689.

PMID 10574256

Comparative genomic hybridization analysis of adrenocortical tumors.

Sidhu S, Marsh DJ, Theodosopoulos G, Philips J, Bambach CP, Campbell P, Magarey CJ, Russell CF, Schulte KM, Rher HD, Delbridge L, Robinson BG

The Journal of clinical endocrinology and metabolism. 2002 ; 87 (7) : 3467-3474.

PMID 12107267

Adrenal cancer.

Stratakis CA, Chrousos GP

Endocrinology and metabolism clinics of North America. 2000 ; 29 (1) : 15-25.

PMID 10732261

Andrenocortical carcinomas: twelve-year prospective experience.

Tauchmanov L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, Palmieri G, Marzano E, Salvatore M, Pettinato G, Lombardi G, Rossi R

World journal of surgery. 2004 ; 28 (9) : 896-903.

PMID 15593464

Characterization of a newly established cell line derived from human adrenocortical carcinoma.

Ueno M, Nakashima J, Akita M, Ban SI, Nakanoma T, Iida M, Deguchi N

International journal of urology : official journal of the Japanese Urological Association. 2001 ; 8 (1) : 17-22.

PMID 11168692

Genetic changes in human adrenocortical carcinomas.

Yano T, Linehan M, Anglard P, Lerman MI, Daniel LN, Stein CA, Robertson CN, LaRocca R, Zbar B

Journal of the National Cancer Institute. 1989 ; 81 (7) : 518-523.

PMID 2564050

Combined comparative genomic hybridization and genomic microarray for detection of gene amplifications in pulmonary artery intimal sarcomas and adrenocortical tumors.

Zhao J, Roth J, Bode-Lesniewska B, Pfaltz M, Heitz PU, Komminoth P

Genes, chromosomes & cancer. 2002 ; 34 (1) : 48-57.

PMID 11921282

Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis.

Zhao J, Speel EJ, Muletta-Feurer S, Rtimann K, Saremaslani P, Roth J, Heitz PU, Komminoth P

The American journal of pathology. 1999 ; 155 (4) : 1039-1045.

PMID 10514385

Citation

This paper should be referenced as such :

Stratakis, CA ; Matyakhina, L

Endocrine/neuroendocrine glands: Adrenal cortical carcinoma

Atlas Genet Cytogenet Oncol Haematol. 2005;9(2):163-165.

Free journal version : [ pdf ]   [ DOI ]

On line version : http://AtlasGeneticsOncology.org/Tumors/AdrenalCorticalCarcinID5088.html

Other genes implicated (Data extracted from papers in the Atlas) [ 16 ]

Genes	CCND1	BUB3	CALR	CDC7	CITED2	GATA6	MAPK6	MCM7	NPY1R	NR0B1
	PDE11A	PRKAR1A	RET	SNAI1	UBE2C	VRK2

External links

arrayMap	Topo ( C74) arrayMap ((UZH-SIB Zurich)   [auto + random 100 samples .. if exist ]   [tabulated segments]
Other database	Adrenocortical carcinoma (ACC) TCGA Copy Number Portal
Other database	Adrenocortical Carcinoma [ Genomic Data Commons - NCI TCGA-ACC]
Disease database	Neuro-Endocrine/Endocrine system: Adrenal cortical carcinoma

REVIEW articles	automatic search in PubMed
Last year articles	automatic search in PubMed

© Atlas of Genetics and Cytogenetics in Oncology and Haematology

indexed on : Mon Dec 14 18:30:15 CET 2020

For comments and suggestions or contributions, please contact us